Cargando…

First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma

BACKGROUND: The usefulness of neoadjuvant chemotherapy for patients with duodenal adenocarcinoma remains unclear. We report the case of a successfully resected duodenal adenocarcinoma managed by neoadjuvant chemotherapy using gemcitabine and S-1. CASE PRESENTATION: A 72-year-old female presented wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, Jiro, Sui, Kenta, Tabuchi, Motoyasu, Murokawa, Takahiro, Sakamoto, Shinya, Iwata, Jun, Matsumoto, Manabu, Okabayashi, Takehiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117578/ https://www.ncbi.nlm.nih.gov/pubmed/35585218 http://dx.doi.org/10.1186/s40792-022-01453-2

Ejemplares similares

Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
por: Murokawa, Takahiro, et al.
Publicado: (2022)

Epithelioid angiosarcoma of the duodenum: a case report
por: Sakamoto, Shinya, et al.
Publicado: (2022)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
por: Tsunemitsu, Ryosuke, et al.
Publicado: (2023)

Clinicopathological features of intraductal papillary mucinous neoplasm derived from ectopic pancreas: A systematic review
por: Kimura, Jiro, et al.
Publicado: (2022)

Exophytic pancreatic lymphoepithelial cyst incidentally detected in a differentiated thyroid cancer patient on whole-body I-131 scan: a case report
por: Murokawa, Takahiro, et al.
Publicado: (2022)

Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer
por: Okabayashi, Takehiro, et al.
Publicado: (2022)

Duodenojejunostomy for endoscopic management of biliary enteric anastomotic stricture inaccessible via balloon-assisted endoscopy: a case report
por: Sakamoto, Shinya, et al.
Publicado: (2023)

Indications for pancreaticoduodenectomy affected postoperative outcomes in octogenarians
por: Okabayashi, Takehiro, et al.
Publicado: (2020)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma
por: Velandia, Carlos, et al.
Publicado: (2018)

Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
por: Seo, Dongjin, et al.
Publicado: (2023)

A case of stage IV gastric cancer with para-aortic lymph node metastasis showing pathological complete response after neoadjuvant chemotherapy
por: Katsura, Yuki, et al.
Publicado: (2020)

Laparoscopic gastric partitioning gastrojejunostomy for an unresectable duodenal malignant tumor
por: Matsumoto, Toshifumi, et al.
Publicado: (2005)

Durable response for ampullary and duodenal adenocarcinoma with a nab‐paclitaxel plus gemcitabine ± cisplatin combination
por: Cen, Putao, et al.
Publicado: (2019)

Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone
por: Murata, Akihiro, et al.
Publicado: (2013)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
por: Kunzmann, Volker, et al.
Publicado: (2014)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas
por: Rogers, S.J., et al.
Publicado: (2021)

Mucinous cholangiocarcinoma: Clinicopathological features of the rarest type of cholangiocarcinoma
por: Sumiyoshi, Tatsuaki, et al.
Publicado: (2017)

Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas
por: Pompa, Tiffany A., et al.
Publicado: (2017)

Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
por: Herman, Joseph M, et al.
Publicado: (2015)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
por: Mie, Takafumi, et al.
Publicado: (2023)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case
por: Tsunematsu, Masashi, et al.
Publicado: (2019)

Primary Duodenal Adenocarcinoma Expressing Carbonic Anhydrase IX
por: Kubo, Kimitoshi, et al.
Publicado: (2022)

Postoperative chylous ascites after total gastrectomy successfully treated using peritoneovenous (Denver) shunt: a case report
por: Sakamoto, Shinya, et al.
Publicado: (2022)

High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma
por: Lv, Wei, et al.
Publicado: (2016)

Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma
por: Inoue, Tadahisa, et al.
Publicado: (2022)

MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Mikamori, Manabu, et al.
Publicado: (2017)

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma
por: Xie, Li, et al.
Publicado: (2019)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

Rare resected eight cases of duodenal adenocarcinomas
por: Nanashima, Atsushi, et al.
Publicado: (2021)

A Case of Streptozocin Monotherapy for Unresectable Duodenal Neuroendocrine Tumor G2
por: Miyagawa, Koji, et al.
Publicado: (2019)

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
por: Habermehl, Daniel, et al.
Publicado: (2012)

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
por: Eto, K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qvbcffovmt2naejv53rg6vl917